financetom
Business
financetom
/
Business
/
Werewolf Therapeutics Q3 net loss narrows on lower R&D expenses
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Werewolf Therapeutics Q3 net loss narrows on lower R&D expenses
Nov 4, 2025 4:25 AM

Overview

* Werewolf Therapeutics ( HOWL ) Q3 net loss narrows slightly from last year

* Research and development expenses decreased in Q3 compared to same period in 2024

* Company received Fast Track Designation for WTX-124 from the US FDA

Outlook

* Werewolf to update on WTX-124 Phase 1/1b trial in Q4 2025

* Company plans WTX-330 trial update in Q4 2025

* Werewolf to nominate WTX-1011 target by year-end 2025

Result Drivers

* Research and development expenses were $11.6 million for the third quarter of 2025, compared to $12.5 million for the same period in 2024

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Net -$16.37

Income mln

Q3 Basic -$0.36

EPS

Q3 $15.72

Operatin mln

g

Expenses

Q3 -$15.72

Operatin mln

g Income

Analyst Coverage

* The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 6 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy."

* Wall Street's median 12-month price target for Werewolf Therapeutics Inc ( HOWL ) is $7.00, about 81.3% above its November 3 closing price of $1.31

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Top Premarket Gainers
Top Premarket Gainers
Jan 13, 2025
08:12 AM EST, 01/13/2025 (MT Newswires) -- Sage Therapeutics ( SAGE ) shares surged nearly 38% in recent Monday premarket activity after it said late Friday Biogen (BIIB) had submitted an unsolicited, nonbinding proposal to acquire all outstanding shares of the company not already owned for $7.22 a share. Intra-Cellular Therapies ( ITCI ) stock rose nearly 35% after it...
Engine manufacturers make improvements in speeding up of deliveries, SMBC CEO says
Engine manufacturers make improvements in speeding up of deliveries, SMBC CEO says
Jan 13, 2025
DUBLIN, Jan 13 (Reuters) - Engine manufacturers have made some improvements when it comes to speeding up delivery delays, SMBC Aviation Capital CEO Peter Barrett told Reuters on Monday, but there is still some way to go. He added that rising costs continue to be a challenge for airlines, including on maintenance, but that demand remains strong and will help...
Ag Growth Cuts 2024 Adjusted EBITDA Outlook
Ag Growth Cuts 2024 Adjusted EBITDA Outlook
Jan 13, 2025
08:15 AM EST, 01/13/2025 (MT Newswires) -- Ag Growth International ( AGGZF ) on Monday cut its full year 2024 adjusted EBITDA outlook to about $260 million with adjusted EBITDA margins of about 18.5%, compared with its previous outlook of adjusted EBITDA of about $280 million with adjusted EBITDA margins of about 19%. In 2023, adjusted EBITDA was $294 million...
Microbix Testing to Ensure Assays Can Detect Avian Flu Strain
Microbix Testing to Ensure Assays Can Detect Avian Flu Strain
Jan 13, 2025
08:14 AM EST, 01/13/2025 (MT Newswires) -- Microbix Biosystems ( MBXBF ) on Monday said it has begun a pilot proficiency testing program to ensure that molecular diagnostic assays can detect the emerging H5N1 strain of the Influenza A virus, or avian flu. The program is being conducted in conjunction with the American Proficiency Institute, which provides proficiency testing programs...
Copyright 2023-2026 - www.financetom.com All Rights Reserved